Xintela AB: BioStock: Xintela initiates last dose level in knee osteoarthritis study
Xintela recently announced that they have initiated the third and last dose level in the phase I/IIa study with the stem cell product XSTEM in patients with knee osteoarthritis. The company's goal is to present safety data from all dose levels and early efficacy results in 2023. BioStock contacted Camilla Wennersten, Director Clinical Development at Xintela, to find out more about the study.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se